Scarica l'app Stockscreener
0.97
2.99%
-0.0299
Dopo l'orario di chiusura:
.97
Precedente Chiudi:
$0.9999
Aprire:
$0.976
Volume 24 ore:
36,758
Relative Volume:
0.88
Capitalizzazione di mercato:
$25.68M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-2.7866
EPS:
-0.3481
Flusso di cassa netto:
-
1 W Prestazione:
-0.31%
1M Prestazione:
-34.01%
6M Prestazione:
-68.66%
1 anno Prestazione:
-66.97%
Intervallo 1D:
$0.95
$1.0138
Intervallo di 1 settimana:
$0.95
$1.13
Portata 52W:
$0.90
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Nome
Akari Therapeutics Plc Adr
Settore
Industria
Telefono
(646) 350-0702
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta AKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.97 | 25.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-01-04 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Aggiornamento | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Reiterato | Chardan Capital Markets | Sell |
| 2016-07-11 | Iniziato | Chardan Capital Markets | Sell |
Mostra tutto
Akari Therapeutics Plc Adr Borsa (AKTX) Ultime notizie
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics names Samir Patel as CEO and adds board member - Investing.com India
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Akari Therapeutics appoints new CFO - Investing.com
Akari Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status | AKTX Stock News - StockTitan
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan
Akari Therapeutics shareholders approve Peak Bio merger - Investing.com
Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Akari Therapeutics PlcADR (AKTX) Price Target Increased by 45.45% to 81.60 - MSN
Akari Therapeutics appoints Rob Bazemore to board - Investing.com
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - StockTitan
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - StockTitan
Akari Therapeutics shareholders approve board and auditors - Investing.com India
Akari Therapeutics shareholders approve board and auditors By Investing.com - Investing.com India
Zoomcar announces departure of President Adarsh Menon By Investing.com - Investing.com
Phillips Edison expands board, appoints Devin Murphy By Investing.com - Investing.com India
Goldman Sachs raises Birkenstock target to $59.50, keeps neutral stance By Investing.com - Investing.com
Shopify’s market position 'promising for growth', Evercore ISI sees stock upside - Investing.com
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Arbe Robotics sees high demand for convertible debt By Investing.com - Investing.com
Insmed executive sells over $270k in company stock By Investing.com - Investing.com
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering - StockTitan
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com Australia
GCI: Best & Worst Performing Small Cap Stocks for July 19, 2019 - StockNews.com
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% - Investing.com
Dow Jones News: Dow Rallies 200 Points After Macron and Le Pen Win First Round of French Election - Money Morning
Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher - Nasdaq
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
Two Stocks That Have Deerfield Management And Anchor Bolt Capital Excited - Insider Monkey
Akari Therapeutics Plc Adr Azioni (AKTX) Dati Finanziari
Non sono disponibili dati finanziari per Akari Therapeutics Plc Adr (AKTX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):